The storage and release of :t H-norepinephrine in the hearts of rats made hypertensive by desoxycorticosterone and NaCl is reported. The initial uptake of the labeled catecholamine was similar in hypertensive and normotensive groups. After an intravenous injection of 3 H-norepinephrine, there was a greater and more prolonged fall in specific activity of cardiac norepinephrine in the first few hours in the hypertensive animals. Subcellular distribution studies showed that in the hearts from hypertensive rats a greater proportion of the labeled amine was present in the soluble-cytoplasmic fraction than in the granular-storage fraction. In control rats an equilibrium between soluble and granular fractions was reached by 1 hr, while in the hypertensives it was not achieved within 24 hr. In the first few hours there was a 45% fall in specific activity in the granular fraction of the hypertensive rats, but only a small reduction in the controls. There was an elevation in the fraction of deaminated metabolites in the hearts of the hypertensive animals, while in the kidneys all 3 H-metabolites were increased. These observations are consistent with the concept that there is a defect in the storage and retention of norepinephrine by granules in sympathetic nerves in this type of experimental hypertension. Such an abnormality might permit increased amounts of physiologically active catecholamine to be available to the receptor.
• Previous work in this laboratory has demonstrated a marked reduction in the accumulation of circulating norepinephrine in the hearts and certain other tissues of rats made hypertensive with desoxycorticosterone (DOC) and a high salt diet (1, 2) . These findings could be the result of reduced uptake of the catecholamines across the sympathetic axonal membranes, increased metabolism or utilization, or a defect in the uptake, retention, or release in the storage granules within the adrenergic nerve terminal. It has already been shown that the initial uptake of norepinephrine is the same in the hearts of normotensive and hypertensive rats (2) . This report will be concerned with studies of the storage, utilization, and metabolism of norepinephrine in experimental hypertension in the rat produced by DOC and NaCl. It will be shown that the defect in norepinephrine storage in experimental hypertension occurs at the level of the storage granule in the sympathetic nerve. 1 
Methods

PREPARATION OF HYPERTENSIVE ANIMALS
Male NIH stock Sprague-Dawley rats weighing 70 to 80 g were prepared by surgical removal of the right kidney. They were given a regular laboratory diet (Purina) and tap water. Hypertension was produced by weekly subcutaneous injections of 0.4 ml of a suspension containing 25 mg desoxycorticosterone trimethylacetate, 10.5 mg methylcellulose, 3 mg carboxymethylcellulose, 1 mg polysorbate 80, and 8 mg NaCl per 584 KRAKOFF, DE CHAMPLAIN, AXELROD ml. In addition these animals received 1% NaCl in tap water ad libitum with regular laboratory diet. Systolic arterial blood pressure was measured and the rise of systolic blood pressure in the animals treated with DOC and NaCl was similar to that previously reported (2) . Although the body weight of hypertensive animals was lower (Table 1) , they appeared healthy. At the time of the killing, no signs of ascites, liver enlargement, or pulmonary effusion were noticed.
TURNOVER STUDIES
Rats were given 2.5 /xc of 3 H-norepinephrine (New England Nuclear, 10.2 c/mmole) iv via a tail vein and killed at various times afterward. Hearts were rapidly removed and analyzed for 3 H-norepinephrine and endogenous norepinephrine by previously described methods (2) (3) (4) (5) . Turnover rates were estimated from the slopes of the change in specific activity of norepinephrine with time.
SUBCELLULAR DISTRIBUTION OF NOREPINEPHRINE
Rats were given 10 to 25 fxc of 3 H-norepinephrine iv and killed at various times. Hearts were rapidly removed, blotted free of blood, and immediately chilled on crushed ice. A portion was homogenized in chilled 0.25 M sucrose for 1 min (20 to 30 strokes) in an all-glass Duall homogenizer for analysis of subcellular localization by a modification of the method of Iversen et al. (6) . The homogenates were transferred to polypropylene tubes and centrifuged for 10 min at 12,000 g in a Sorval RC-2 refrigerated centrifuge. The resulting pellet contained unbroken cells, nuclei, debris, and mitochondria. The supernatant fraction was then transferred to cellulose nitrate tubes and placed in a Spinco L-2 preparative ultracentrifuge with a no. 40 rotor and centrifuged at 100,000 g for 1 hr to give a pellet containing the catecholamine storage granules as well as other microsomal elements. The supernatant fluid was decanted and acidified with 1/9 volume of 4 N HC10 4 . The pellets were suspended and homogenized in 0.4 N HC10 4 and all three fractions were assayed for 3 H-norepinephrine and endogenous norepinephrine.
ASSAY OF "H-NOREPINEPHRINE AND ITS METABOLITES
Hearts and kidneys of rats were removed 30 min after an intravenous injection of 50 fj,c of 3 H-norepinephrine, tritiated norepinephrine and its metabolites were determined by column chromatography with alumina and Dowex 50 for the amines and by solvent extraction for the acidic and alcoholic metabolites as previously described (7) . Conjugated metabolites present in the kidney were determined after 24-hr incubation at 37°C with Glusulase (Endo Laboratories). This procedure hydrolyzed both glucuronide and sulfate conjugates. H-norepinephrine and groups of 6-10 animals were killed at various times after injection. Results are expressed as mean ± SEM. TJ2 and rate constants are derived from Figure 1 . Synthesis rates are calculated from the rate constant and endogenous norepinephrine levels according to the method of Costa et al. (8) .
•P<0.01.
Results
RATE OF DISAPPEARANCE OF "H-NOREPINEPHRINE FROM HEARTS OF HYPERTENSIVE AND NORMAL RATS
Rats were treated with DOC and NaCl for 4 weeks, then given a tracer dose of tritiated norepinephrine. Cardiac norepinephrine and 3 H-norepinephrine were then determined at various time intervals from 5 min to 24 hr. The systolic blood pressure of the DOC-and NaCl-treated group was markedly above that of the controls ( Table 1 ). The accumulation of 3 H-norepinephrine at 5 min was not significantly different between the control and hypertensive groups, but at 24 hr a marked difference was apparent. Endogenous norepinephrine content of the hearts of the hypertensive rats was reduced.
Changes in specific activity of cardiac norepinephrine over a 24-hr period are shown in Figure 1 . In the normotensive rat hearts there was a rapid fall in specific activity from 5 min to 1 hr followed by a slower monophasic decline throughout the remainder of the experiment.
The initial specific activity was higher in the hypertensives (P < 0.01) than in the controls owing to the lower endogenous norepinephrine levels in the hypertensive rats. However, the period of rapid decline of specific activity in the hypertensives was markedly prolonged so that by 4 hr the specific activity of the hypertensives was below that of controls. At this time the rate of change of specific activity became linear. The later portions of these curves represent turnover which included release, metabolism, within and outside the nerve as well as removal by the circulation. Although there was a more rapid turnover in the hypertensives because of the large variation in the values of norepinephrine in the hypertensive group, it was not found to be significantly different from the controls. Estimates of the rates of norepinephrine synthesis in the steady state in the hearts of hypertensive and control animals did not show any significant difference (Table 1) .
SUBCELLULAR DISTRIBUTION OF NOREPINEPHRINE IN HYPERTENSIVE HEARTS
Rats were given 3 H-norepinephrine iv and killed at various times afterward. Hearts were analyzed for the labeled and endogenous norepinephrine content of various subcellular fractions (see Methods). At 5 min the supernatant fraction of the hypertensive rat heart contained slightly more 3 H-norepinephrine than the control while the granular fraction The mean ± SEM per heart is given. Six to eight animals were used for each group and the endogenous norepinephrine levels represent combined 5-min and 4-hr groups. SA =: specific activity.
Subcellular Distribution of Norepinephrine (NE) in Hearts from Control (C) and Hypertensive (H) Rats
•Totals include low speed (12,000 g) fraction which contains mitochondria, muclei and unbroken cells. contained approximately the same amounts (Table 2) . After 4 hr, there was little change in the 3 H-norepinephrine content of the granular fraction of the controls while in the hypertensives there was marked decrease. Though there was a fall in the 3 H-norepinephrine content of the supernatant fraction in both controls and hypertensives, the decline was greater in the hypertensives. At 4 hr the amount of 3 H-norepinephrine in both the granular and supernatant fractions of hearts of hypertensive rats was less than that of controls. Changes in the specific activity of cardiac a H-norepinephrine in the granular and supernatant fractions from 5 min to 4 hr are shown in Figure 2 . The greater decrease in specificactivity in the granular fraction of the hypertensive hearts is apparent.
In the controls the ratio of the specific activity of 3 H-norepinephrine of the supernatant to that of the granular fraction was greater than 1.0 at 1 and 5 min, but rapidly fell to 0.91 by 1 hr and remained at that level thereafter in agreement with previous reports (9, 10) (Fig. 3) . This indicates that an equilibrium in the intracellular distribution of 3 H-norepinephrine was reached within 1 hr. In the hearts of hypertensive rats, the proportion of all times. Although this ratio fell, unlike the control group it did not reach a constant value within 24 hr.
The endogenous catecholamine content of the subcellular fractions of the hypertensive hearts was lower than that of the controls; however, in contrast to the changes seen with labeled catecholamine, the proportions of endogenous norepinephrine in the granular and supernatant fractions of hearts from hypertensive and control animals were similar (Table 2).
METABOLISM OF 3 H-NOREPINEPHRINE IN HEARTS AND KIDNEYS OF HYPERTENSIVE RATS
:i H-metabolites remaining in the hearts and kidneys of hypertensive and control rats were examined 30 min after an intravenous injection of 8 H-norepinephrine.
At this time, in the heart there was no significant difference in the content of 3 H-norepinephrine between the two groups ( Table 3 ). In the hypertensives a significant increase in deaminated catechols and O-methylated deaminated catechols was apparent, but there was ± 0.9* ± 0.6 ± 1.5* ± 0.089f ± 0.075f % Change
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Results are expressed as counts per minute ± SEM X 10-3 per heart. Numbers in parentheses indicate the number of animals in each group.
•P < 0.01. tP < 0.05. 
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no difference in the content of 3 H-normetanephrine. The pattern of metabolites in the kidneys of hypertensive and control animals is shown in Table 4 . In contrast to the heart, the major fraction of radioactivity was found to be made up of free and conjugated metabolites. The total amount of 3 H-metabolites was greater in the hypertensives as previously reported (2), though the 3 H-norepinephrine concentration was similar. Of the 3 H-metabolites, free 3 H-normetanephrine fraction showed the greatest increase in the hypertensives as compared to controls. Although there was a marked enlargement of the kidney of hypertensive animals, no other pathological difference could be observed on gross examination between kidneys from hypertensive or control animals.
Discussion
The present results confirm previous findings of a marked reduction of 3 H-norepinephrine accumulation in the hearts of hypertensive animals. This reduction is not due to a decrease in initial uptake across axonal membranes (2) . A study of the changes in specific activity of the 3 H-norepinephrine remaining in the hypertensive hearts at various times indicates an inability to retain newly taken up norepinephrine. When norepinephrine is taken up from the circulation by adrenergic neurons, it undergoes several discrete subcellular movements, involving transport across axonal membranes to intraneural cytoplasm, followed by uptake and retention by the storage granules (11) . The initial rapid changes in specific activity of 3 H-norepinephrine reflect this transfer of a fraction of the norepinephrine taken up by adrenergic neurons to its storage site and disappearance of the remainder by metabolism, washout, and release. In the hypertensive animals, the period of rapid fall in specific activity was prolonged, suggesting that the reduced retention of norepinephrine by the adrenergic neurons of the hypertensive animals may be due to abnormalities in the storage sites.
Subcellular distribution studies indicate that the intraneuronal storage granules of the hypertensives are defective. The initial rapid loss of labeled norepinephrine from the microsomal fraction [which contains the norepinephrine storage granules (12) ] of the hypertensive hearts suggests that there is a defect in binding capacity. The ratio of the specific activity of the supernatant to the specific activity of the granular fraction does not reach a constant level by 24 hr. In the controls the ratio becomes constant within 1 hr. This indicates that in the hypertensive rats there is a disproportionate loss of labeled norepinephrine from the storage granules to the cytoplasm.
The immediate uptake by the storage granules is distinct and different from binding and retention (13) . This process may also be impaired in the hypertensive animals since the proportion of newly taken up norepinephrine in the supernatant fraction (presumably neural cytoplasm) at 1 min is greater in the hypertensives than in controls (see Fig. 3 ).
Some of the norepinephrine that spontaneously leaves the storage granules is inactivated by monoamine oxidase within the nerve (14) . That portion of physiologically active norepinephrine which is released by the nerve, is either taken up again into the nerve, Omethylated by catechol-O-methyl transferase or removed by the circulation (15). Circulating catecholamines are then mainly metabolized by O-methylation in liver and kidney (16). The increased fraction of deaminated metabolites in the hearts of the hypertensives suggests that more "cytoplasmic" norepinephrine is available for intraneural deamination (14) . The increase in deaminated metabolites could also be a consequence of the elevated Circulation Research, Vol. XXI, November 1967 monoamine oxidase activity found in hypertensive hearts. However, the change in monoamine oxidase activity appears related to cardiac enlargement and has been shown to be unrelated to the size of the norepinephrine storage pool (17).
The marked increase in the proportion of the O-methylated amine in the kidneys of the hypertensive rats indicates that there has also been a greater release of physiologically active norepinephrine and consequent metabolism by catechol-O-methyl transferase. Thus the shift in the intraneural distribution of norepinephrine caused by the altered binding properties of the storage granules appears to make more norepinephrine available for release of the physiologically active transmitter by adrenergic neurones.
A defect in intraneural granular function might explain the reduction in endogenous norepinephrine in this form of experimental hypertension. Estimated synthesis rates for cardiac norepinephrine in hypertensive and normotensive groups are quite similar. Also the rate of conversion of 14 C-tyrosine to 14 Ccatecholamines is the same in hypertensive and normotensive rats (de Champlain and Krakoff, unpublished observations). Thus there is no evidence at the present time for an abnormality in the production of norepinephrine in experimental hypertension in contrast to that seen in experimental congestive heart failure (18).
The state of sodium balance plays a role in norepinephrine storage (17) and changes in the ionic environment of the sympathetic neuron within the cardiovascular system may act on the uptake and binding properties of the adrenergic neurons. Since there is evidence that granular binding is enhanced by ATP (13), the availability of this compound may also be relevant to the changes in binding capacity of the adrenergic neuron in experimental hypertension. A schematic representation of this defect in the storage of norepinephrine in the sympathetic neurone of hearts of rats is shown in Figure 4 .
The precise relationship between the elevation of blood pressure and the reduction of binding capacity in DOC-NaCl hypertension cannot be stated at this time. However, it has been observed that the reduction in 3 Hnorepinephrine accumulation may precede the development of elevated blood pressure (Krakoff and de Champlain, unpublished observations). Whether this change participates in the causation and maintenance of high blood pressure remains to be clarified.
